XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its leading candidate drug has been selected for a presentation at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9th-12th.
The abstract, titled Autologous NK Cells as Consolidation After Front-Line Stem Cell Transplantation in Multiple Myeloma: A Long-Term Follow-Up, will be presented by the first author Johan Lund at a poster session on Friday, June 10, 16:30 – 17:45 CEST. The other authors include Hareth Nahi, Stephan Meinke, Per-Henrik Holmqvist, Hans-Gustaf Ljunggren, Johan Aschan and Evren Alici.
“We are very happy to be able to present this clinical long-term follow-up at this prestigious conference. It further strengthens our belief in this exciting clinical program, which also includes an ongoing clinical Phase II combination study with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab)”, said XNK’s CMO Johan Aschan.
For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company is at the forefront of the development of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and lead investigational candidate drug was developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable. The Company’s objective is for its investigational candidate drug and proprietary platform technology to constitute key components in the cancer treatments of tomorrow. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit xnktherapeutics.com.
First-in-human Phase I/II clinical trial was conducted at the Hematology Center, Karolinska University Hospital, Stockholm, Sweden, in a setting of consolidation treatment following high dose autologous stem cell transplantation in patients newly diagnosed with Multiple myeloma. The clinical study was an open, single-arm, triple escalating dose/patient study with the primary objective of studying the safety and tolerability of the product. The product demonstrated a high degree of safety, and no severe adverse events (SAE) were reported. The secondary objectives included deepening in the response, i.e., further decrease in serum Ig level (M-protein) in patients who did not achieve complete remission and deepening of minimal residual disease (MRD) in patients achieving complete remission. Four out of six patients had measurable disease following autologous SCT. Out of these four patients, all showed objective measurable responses to NK cell infusion in terms of reduction in M-component and/or MRD. The explorative analysis allowed extensive characterization of infused NK cells in patients. The treatment strategy opens for the usage of autologous NK cells in clinical settings.